Recent Quotes

My Watchlist

Indicators

Currencies

International

Treasuries

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

84.02 -0.63 (-0.74%)

Streaming Delayed Price Updated: 12:51 PM EDT, Aug 3, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	560,050
Open	84.81
Bid (Size)	83.87 (300)
Ask (Size)	84.02 (400)
Prev. Close	84.65
Today's Range	81.61 - 85.96
52wk Range	15.01 - 95.49
Shares Outstanding	105,736,200
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia

July 27, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Top movers analysis in the middle of the day on 2026-07-22: top gainers and losers in today's session. ↗

July 22, 2026

Via Chartmill

Performance

YTD	+23.9%	+23.9%
1 Month	-2.9%	-2.9%
3 Month	+10.0%	+10.0%
6 Month	+15.1%	+15.1%
1 Year	+410.3%	+410.3%

More News

Gapping stocks in Wednesday's session ↗

July 22, 2026

Via Chartmill

These stocks are moving in today's pre-market session ↗

July 22, 2026

Via Chartmill

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Soars 70% After Hours on REDEMPLO Launch Momentum and Strong Q2 Earnings Beat ↗

May 07, 2026

Via Chartmill

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

July 22, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

July 21, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)

June 22, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars

June 18, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Lines Up SHASTA Readout as REDEMPLO Launch Gains Traction ↗

June 05, 2026

Via MarketBeat

Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events

June 02, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026

May 27, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress

May 26, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum ↗

May 20, 2026

Via MarketBeat

Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near ↗

May 14, 2026

Via MarketBeat

Arrowhead (ARWR) Q2 2026 Earnings Transcript ↗

May 08, 2026

Via The Motley Fool

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

May 07, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals

May 05, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events

May 04, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)

May 01, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

What's going on in today's after hours session ↗

April 29, 2026

Via Chartmill

Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe

April 24, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results

April 20, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Emerges as a Growth Stock with a Constructive Technical Setup ↗

April 11, 2026

Via Chartmill

Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo

March 28, 2026

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Frequently Asked Questions

Is Arrowhead Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Arrowhead Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Arrowhead Pharmaceuticals, Inc. - Common Stock trade on?

Arrowhead Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Arrowhead Pharmaceuticals, Inc. - Common Stock is ARWR on the Nasdaq Stock Market

What is the current price of Arrowhead Pharmaceuticals, Inc. - Common Stock?

The current price of Arrowhead Pharmaceuticals, Inc. - Common Stock is 84.02

When was Arrowhead Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Arrowhead Pharmaceuticals, Inc. - Common Stock was at 08/03/26 12:51 PM ET

What is the market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Arrowhead Pharmaceuticals, Inc. - Common Stock is 8.88B

How many shares of Arrowhead Pharmaceuticals, Inc. - Common Stock are outstanding?

Arrowhead Pharmaceuticals, Inc. - Common Stock has 9B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.